Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 161

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Human antibodies against amyloid β peptide: A potential treatment for Alzheimer's disease

Dodel, Richard, Hampel, Harald, Depboylu, Candan, Lin, Suizhen, Gao, Feng, Schock, Sabine, Jäckel, Steffi, Wei, Xing, Buerger, Katharina, Höft, Christine, Hemmer, Bernhard, Möller, Hans‐Jürgen, Farlow, Martin, Oertel, Wolfgang H., Sommer, Norbert, Du, Yansheng · 2002 · Annals of Neurology

Abstract

Naturally occurring antibodies directed against β‐amyloid (Aβ) were detected in intravenous immunoglobulin preparations. After intravenous immunoglobulin treatment in patients with different neurological diseases, total Aβ and Aβ 1‐42 in the cerebrospinal fluid was reduced significantly compared with baseline values. In the serum, total Aβ levels increased after intravenous immunoglobulin treatment, whereas no significant change was observed in Aβ 1‐42 levels. Antibodies against Aβ were found to be increased in the serum and cerebrospinal fluid after intravenous immunoglobulin treatment. This study provides evidence that intravenous immunoglobulin or purified Aβ antibodies may modify Aβ and Aβ 1‐42 levels, suggesting potential utility as a therapy for Alzheimer disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ana.10253

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 161

Metadata

Authors
Dodel, R., Hampel, H., Depboylu, C., Lin, S., Gao, F., Schock, S., Jäckel, S., Wei, X., Buerger, K., Höft, C., Hemmer, B., Möller, H., Farlow, M., Oertel, W. H., Sommer, N., & Du, Y.
Venue
Annals of Neurology
Publisher
Wiley
Published
2002-07-23
Volume
52
Issue
2
Pages
253-256
ISSN
  • 0364-5134 (ISSN-L)
  • 1531-8249
OpenAlex
W2085326534
Cited by
161
References
9
FWCI
2.76
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.